saved
Nicotine pouch pharmacokinetics compared to smoked tobacco
Hraness wrote this summary from a saved copy of the source. Quotations are taken word for word from the source.
gist
This systematic review and meta-analysis of seven small crossover trials finds that 4 mg nicotine pouches deliver about 92% of a cigarette's total nicotine exposure but only about 69% of its peak, reached far more slowly. Higher doses and some flavours match or exceed cigarettes, so the authors flag dependence risk; most trials were industry-funded.
ideas
- Similar total, lower and slower peak. Pooled across three trials, 4 mg pouches reached 91.73% of cigarette AUC and 69.15% of cigarette Cmax; pouches peak in about 20 to 65 minutes versus 5 to 8 for cigarettes.
- Dose and formulation matter. Pouches of 8 mg and above, high-freebase formulations, and some flavours and brands matched or exceeded cigarette exposure, with a 30 mg pouch reaching 29.4 ng/mL.
- Mild side effects, short trials. No serious adverse events were reported; headaches, hiccups, nausea and mouth irritation were among the complaints.
- Thin, conflicted evidence. Only seven trials with 15 to 62 participants qualified, risk of bias ranged from low to high, certainty was rated moderate, and five trials were funded by tobacco companies.
quotes
“Lower nicotine doses of NPs result in lower AUC than cigarettes, while higher doses, especially 8 mg and above, result in higher AUC values.”
“Nicotine uptake from NPs can meet or exceed that from conventional cigarettes.”
“NP use may lead to nicotine dependence.”
“NPs were well tolerated, with no serious adverse events reported.”